OPXA News Alert Opexa Therapeutics (OPXA) 0.71 12/17/2014 04

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Opexa Therapeutics (OPXA) 0.71 $OPXA

Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT.
OPXA: 0.71 (-0.03), ATNM: 5.63 (-0.02), AKER: 2.99 (+0.01), CGIX: 6.29 (+0.12)

Small Cap Profiles: OPXA, NEWC, TRNS, MLER
ACCESSWIRE - Thu Dec 11, 9:35AM CST
WHITEFISH, MT / ACCESSWIRE / December 11, 2014 /
TRNS: 9.96 (+0.01), BIIB: 325.13 (-10.67), OPXA: 0.71 (-0.03), SNY: 45.38 (+0.98)

Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 18, 8:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the "Top 10 Advanced Therapy Projects to Watch" by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.
OPXA: 0.71 (-0.03)

Pieris Appoints Michael Richman as Supervisory Board Member
Marketwired - Wed Nov 12, 9:15AM CST
Pieris AG announced today the appointment of Michael Richman as a member of its Supervisory Board.
OPXA: 0.71 (-0.03)

Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference
Business Wire - Tue Nov 11, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November 12 - 13, 2014, at the Apella in New York.
OPXA: 0.71 (-0.03)

Update: Opexa Q3 Earnings, Buyout Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 4:52AM CST

OPXA: 0.71 (-0.03), MRK: 56.80 (-0.15)

Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 3:02PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company's recent corporate developments.
OPXA: 0.71 (-0.03)

Opexa reports November 6
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:50AM CST

OPXA: 0.71 (-0.03)

Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2014 after the close of trading on Thursday, November 6th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EST on Thursday, November 6th.
OPXA: 0.71 (-0.03)

Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS
Business Wire - Wed Oct 22, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit's annual Houston area Walk MS fundraisers for the fourth consecutive year.
OPXA: 0.71 (-0.03)

Opexa Therapeutics to Present at Cleveland Clinic's 12th Annual Medical Innovation Summit
Business Wire - Mon Oct 20, 8:03AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company's President and Chief Executive Officer, has been invited to present at the Cleveland Clinic's 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in Cleveland, Ohio.
OPXA: 0.71 (-0.03)

Opexa Therapeutics Announces Analyst and Investor Event
Business Wire - Thu Oct 02, 1:09PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2014.
OPXA: 0.71 (-0.03)

Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent
Business Wire - Mon Sep 29, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced the expansion of its intellectual property portfolio. Opexa's intellectual property portfolio has grown to reach 98 issued and validated patents worldwide. Additionally, Opexa is expanding its IP protection to cover B-cell mediated diseases in connection with its recently announced development program in Neuromyelitis Optica.
OPXA: 0.71 (-0.03)

Investors look to Lighten Up on Shares of Opexa Therapeutics, Shares Down 7.6% (OPXA)
Comtex SmarTrend(R) - Thu Sep 25, 11:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's worst performing penny stocks, down 7.6% to $0.85 on 1.3x average daily volume. Thus far today, Opexa Therapeutics has traded 316,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -1.5%) and underperformed the S&P 500 (-7.6% to the S&P's -1.5%) during today's trading.
OPXA: 0.71 (-0.03)

Opexa Therapeutics Up 5.6%, Shares Break Through Resistance (OPXA)
Comtex SmarTrend(R) - Thu Sep 18, 10:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's best performing low-priced stocks, up 5.6% to $1.14 on 1.1x average daily volume. Opexa Therapeutics has traded 211,000 shares thus far today, vs. average volume of 200,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's 0.5%) and outperformed the S&P 500 (5.6% to the S&P's 0.4%) during today's trading.
OPXA: 0.71 (-0.03)

Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock
Business Wire - Tue Sep 16, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15, 2014. The termination results from an assessment by Opexa's management that current market conditions are not conducive for an offering on terms that would be in the best interests of Opexa's stockholders. As a result of such termination, no shares will be sold pursuant to the offering.
OPXA: 0.71 (-0.03)

Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
OPXA: 0.71 (-0.03), PSTI: 2.47 (-0.07), CYTX: 0.47 (-0.04), OSIR: 13.13 (+0.16), NVS: 91.65 (+0.01), CELGZ: 3.29 (-0.18)

Market Maker Surveillance Report. NPSP, RADA, MGPI, OPXA, RLOC, NETE, Losing Stocks With Lowest Price Friction For Monday, September 15th 2014
M2 - Tue Sep 16, 5:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 1512 companies with positive Friction Factors and 3686 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Rada Electronic Industries Ltd (NASDAQ:RADA), MGP Ingredients Inc (NASDAQ:MGPI), Opexa Therapeutics Inc (NASDAQ:OPXA), REACHLOCAL INCORPORATION (NASDAQ:RLOC), NET ELEMENT INC (OTC:NETE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NETE: 1.11 (unch), OPXA: 0.71 (-0.03), RADA: 2.51 (+0.07), NPSP: 30.47 (+0.39), RLOC: 3.27 (+0.12), MGPI: 15.58 (-0.14)

Opexa Therapeutics to issue public offering of common shares
M2 - Tue Sep 16, 5:57AM CDT
Biopharmaceutical company company Opexa Therapeutics (NasdaqCM:OPXA) said on Monday that it plans to offer shares of its common stock in a public offering.
OPXA: 0.71 (-0.03)

Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Business Wire - Mon Sep 15, 3:21PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Opexa. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
OPXA: 0.71 (-0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 112

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 160

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 135

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 157

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 142

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 118

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading

Top 5 Most Recently Viewed Articles

Health-Ade Partners with Wheel of Fortune and Ryan Seacrest

Updated Category News Views 212

Health-Ade Shines at Wheel of Fortune Premiere Health-Ade is thrilled to announce its prominent involvement in the premiere week of the classic game show, Wheel of Fortune, as it embarks on an exciting new journey with Ryan Seacrest as the show's host. This is an exhilarating moment not only for Wheel of Fortune but also for Health-Ade Kombucha, which is celebrated for...

Continue Reading
Investment Fund Trends and Insights for October 2024

Updated Category News Views 101

Mutual Fund and ETF Asset Management In the scope of mutual funds and exchange-traded funds (ETFs), the latest insights reveal a steady growth in assets and sales throughout the investment landscape. As investors look for diverse options, investment funds have shown resilience and dynamic adaptability, showcasing robust growth metrics in their respective categories....

Continue Reading
S&P and Pantera Take Digital Asset Indexing to New Heights

Updated Category News Views 18

Digital Assets: A New Benchmark in Town Date it, folks: July 21, 2026. S&P Dow Jones Indices and Pantera Capital are rolling out a fresh digital asset index. They're slapping the 'S&P Pantera' name on something focused less on the casino vibe you get from memes and Bitcoin mania, and more on actual economic value and real-world use. Flipping the script on the way most of...

Continue Reading
Gundry MD Wins Big with Innovative Softgel Formula

Updated Category News Views 57

Breaking New Ground in Weight Management Forget the caffeine-laden pills and appetite-killer potions—here comes something that simply whispers to your gut and says, "Manage your weight naturally." That's what Gundry MD's Daily Weight Advantage™ has cooked up, bagging the prestigious NutraIngredients-USA's Weight Management Product of 2026 award. Finally, a product...

Continue Reading
Ciena's Options Market Insights: Bullish Trends and Growth Prospects

Updated Category News Views 202

Understanding Ciena's Recent Options Activity Investors with significant resources have shown a clear bullish sentiment towards Ciena (NYSE: CIEN), indicating crucial trends that market observers should consider. By monitoring options records, it’s clear that substantial movements are occurring within the CIEN stock, hinting that noteworthy developments might be on the...

Continue Reading